Insight Molecular Diagnostics Reports Q2 2026 Results; FDA AIR

What Happened

• On August 10, 2026, Insight Molecular Diagnostics, Inc. (iMDx) issued a press release announcing its financial results for the three and six months ended June 30, 2026. The press release is furnished as Exhibit 99.1 to the 8‑K.
• The Company also disclosed it received an Additional Information Request (AIR) from the U.S. Food and Drug Administration (FDA) regarding its submission for GraftAssureDx. iMDx must provide a complete response to the AIR within 180 days and expects one more meeting with the FDA before the fourth quarter of 2026. The Company characterized the AIR as a routine part of the FDA review process and said it is prepared to respond.

Key Details

• Filing date: August 10, 2026 (Form 8‑K).
• Financial results cover the three and six months ended June 30, 2026; detailed figures are in Exhibit 99.1 (press release).
• FDA action: Additional Information Request for GraftAssureDx; complete response due within 180 days.
• Company expects one more meeting with the FDA before Q4 2026 and views the AIR as routine.

Why It Matters

• Earnings/financial results: The press release contains the company's most recent quarterly performance and condition; investors should review Exhibit 99.1 for revenue, profit/loss, cash position and trends that affect valuation and near‑term financing needs.
• Regulatory timeline: The FDA AIR establishes a 180‑day response window and signals the regulatory review is active. The Company’s planned follow‑up meeting with the FDA and its readiness to respond are key near‑term catalysts to monitor for developments on GraftAssureDx approval and commercialization.